pertuzumab (perjeta°) after surgery for some breast cancers at high risk of recurrence

首页> 外文期刊>Prescrire international >pertuzumab (perjeta°) after surgery for some breast cancers at high risk of recurrence

【24h】

pertuzumab (perjeta°) after surgery for some breast cancers at high risk of recurrence

机译：Pertuzumab（perjeta°）手术后的一些乳腺癌，高风险的疾病

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Pertuzumab compared to placebo: survival rate the same and risk of invasive disease almost unchanged, but a higher risk of adverse effects, in particular heart failure. PERJETA° - pertuzumab concentrate for solution for intravenous infusion, 420 mg of pertuzumab (30mg/ml) per 14 ml vial, antineoplastic; anti-HER2 monoclonal antibody, New indication: "in combination with trastuzumab and chemotherapy in (...) the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence". [EU centralised procedure]. In women with non-metastatic breast cancer, surgical excision is the standard treatment. Adjuvant chemotherapy, i.e. after surgery, is often proposed, in order to prolong survival or reduce the risk of local recurrence and metastasis. When the tumour over-expresses the HER2 protein, addition of trastuzumab (a monoclonal antibody with anti-HER2 activity) to adjuvant chemotherapy prolongs survival (1,2).

机译：Pertuzumab与安慰剂相比：生存率相同和侵袭性疾病的风险几乎没有改变，但不良反应的风险较高，特别是心力衰竭。 perjeta° - Pertuzumab浓缩物用于静脉内输注的溶液，每14ml小瓶420mg pertuzumab（30mg / ml），抗肿瘤; 抗HER2单克隆抗体，新分子：“与（...）伴有曲妥珠单抗和化疗组合成年患者的辅助治疗HER2阳性早期乳腺癌的高危险患者。 [欧盟集中手术]。在患有非转移性乳腺癌的女性中，手术切除是标准治疗。佐剂化疗，即手术后，通常提出，以延长存活或降低局部复发和转移的风险。当肿瘤过度表达HER2蛋白时，添加曲妥珠单抗（具有抗HER2活性的单克隆抗体），延长存活（1,2）。

著录项

来源
《Prescrire international》 |2019年第210期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. pertuzumab (perjeta°) after surgery for some breast cancers at high risk of recurrence [J] . Prescrire international . 2019,第210期

机译：Pertuzumab（perjeta°）手术后的一些乳腺癌，高风险的疾病
2. Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy. [J] . Truong PT, Jones SO, Kader HA, International Journal of Radiation Oncology, Biology, Physics . 2009,第2期

机译：保留乳房手术和全乳放疗后，淋巴结阴性的t1至t2乳腺癌患者的局部和区域复发风险较高。
3. A case-control study on risk factors for local recurrences or distant metastases in breast cancer patients treated with breast-conserving surgery. [J] . Noguchi S, Koyama H, Kasugai T, Oncology: International Journal of Cancer Research and Treatment . 1997,第6期

机译：保乳手术治疗的乳腺癌患者局部复发或远处转移的危险因素的病例对照研究。
4. Sparse Representation of Multi Parametric DCE-MRI features using K-SVD for Classifying Gene Expression Based Breast Cancer Recurrence Risk [C] . Majid Mahrooghy, Ahmed B. Ashraf, Dania Daye, Conference on computer-aided diagnosis . 2014

机译：使用K-SVD对基于基因表达的乳腺癌复发风险进行分类的多参数DCE-MRI特征的稀疏表示
5. The Diet Activity and Lifestyle (DiAL) Study: Risk Perception for Recurrence and Dietary Intake of Breast Cancer Survivors [D] . Winston, Rachel 2012

机译：饮食活动和生活方式（DiAL）研究：乳腺癌幸存者复发和饮食摄入的风险感知
6. A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists the Van Nuys Prognostic Index the Memorial Sloan Kettering Cancer Center DCIS Nomogram and the 12-Gene DCIS Score Assay [O] . Rachel Y. Lei, Dennis L. Carter, Andrew G. Antell, 2021

机译：乳腺辐射脑药学前乳腺癌癌患者预测的同侧肿瘤复发风险的比较乳房辐射手术后乳房辐射手术Van Nuys预后指数纪念斯隆kettering癌症中心DCIS invogram以及12-基因DCIS得分测定
7. CC4 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA [O] . X. Guan, H. Li, Q. Chen, 2019

机译：CC4与曲妥珠单抗和化疗的CC4成本效益分析与曲妥珠单抗和化疗在中国高等乳腺癌患者的佐剂治疗中的佐剂治疗相比

pertuzumab (perjeta°) after surgery for some breast cancers at high risk of recurrence

摘要

著录项

相似文献

相关主题

期刊订阅